Expert Review of Cardiovascular Therapy最新文献

Alternative options to thermal ablation for atrial fibrillation: the role of pulsed field ablation in reducing complications and maintaining efficacy. 房颤热消融的替代选择：脉冲场消融在减少并发症和维持疗效中的作用。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-05 DOI: 10.1080/14779072.2025.2569402

Elio Zito, Vincenzo Mirco La Fazia, Carola Gianni, Bryan Macdonald, Angel Mayedo, Premgeeta Torlapati, Sanghamitra Mohanty, Claudio Tondo, Andrea Natale

{"title":"Alternative options to thermal ablation for atrial fibrillation: the role of pulsed field ablation in reducing complications and maintaining efficacy.","authors":"Elio Zito, Vincenzo Mirco La Fazia, Carola Gianni, Bryan Macdonald, Angel Mayedo, Premgeeta Torlapati, Sanghamitra Mohanty, Claudio Tondo, Andrea Natale","doi":"10.1080/14779072.2025.2569402","DOIUrl":"10.1080/14779072.2025.2569402","url":null,"abstract":"Introduction: Catheter ablation has traditionally been performed using thermal modalities, which, despite being effective, remain associated with potentially severe complications such as pulmonary vein stenosis and atrioesophageal fistula. Pulsed field ablation (PFA), a non-thermal technique based on irreversible electroporation, has emerged as a promising alternative, with the potential to maintain the efficacy of thermal energies while minimizing collateral damage to surrounding structures.Areas covered: This review discusses the safety and efficacy of PFA for atrial fibrillation (AF) ablation. We analyzed the latest clinical evidence on PFA lesion durability and effectiveness, integrating insights from our clinical experience and workflow. The safety profile of PFA is critically examined, highlighting its advantages in reducing complications while addressing emerging PFA-specific adverse effects such as hemolysis and coronary vasospasm.Expert opinion: PFA promises to overcome the safety limitations encountered during AF ablation with thermal modalities. This may permit earlier referrals, treatment of more complex patients, and adoption of a more individualized, extensive ablation approach. Despite this, PFA still requires technological and workflow optimization due to challenges in lesion durability, real-time lesion assessment, and emerging concerns about energy-specific side effects. These issues require operator awareness and are expected to be addressed with second-generation PFA systems.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":2.1,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed. 降低低密度脂蛋白水平预防动脉粥样硬化性心血管疾病的新疗法：达到其他疗法未能达到的目标。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-02 DOI: 10.1080/14779072.2025.2570839

Artur Dziewierz, Beata Bobrowska, Witold Streb, Francesco Pelliccia, Stanisław Bartuś, Renata Rajtar-Salwa

{"title":"Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed.","authors":"Artur Dziewierz, Beata Bobrowska, Witold Streb, Francesco Pelliccia, Stanisław Bartuś, Renata Rajtar-Salwa","doi":"10.1080/14779072.2025.2570839","DOIUrl":"https://doi.org/10.1080/14779072.2025.2570839","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of global morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) established as a primary causal factor. Despite foundational therapies, many high-risk patients fail to achieve optimal LDL-C targets.Areas covered: This review examines established LDL-C lowering agents (statins and ezetimibe), detailing their mechanisms and limitations, including statin intolerance and residual cardiovascular risk. We provide a comprehensive analysis of novel therapeutic options, including proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators (monoclonal antibodies, small interfering RNA, and emerging oral agents), ATP-citrate lyase inhibitors (bempedoic acid), angiopoietin-like protein 3 (ANGPTL3) inhibitors, and pioneering gene-editing technologies. We discuss mechanisms of action, pivotal efficacy data (LDL-C reduction and plaque modification), safety profiles, and key findings from major cardiovascular outcome trials.Expert opinion: Novel LDL-C lowering therapies represent a paradigm shift, offering unprecedented efficacy in reducing LDL-C and mitigating ASCVD risk. However, significant challenges remain, including cost-effectiveness concerns, the need for long-term safety data, profound global disparities in access, and persistent clinical inertia that impedes real-world implementation even in well-resourced healthcare systems. Future research should prioritize personalized lipid management, combination strategies, and development of durable, cost-effective solutions to reduce the residual ASCVD burden.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming an underdiagnosed respiratory condition: should more patients with cardiovascular complications be screened for obstructive sleep apnea? 克服未确诊的呼吸系统疾病：是否应该对更多心血管并发症患者进行阻塞性睡眠呼吸暂停筛查？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1080/14779072.2025.2551668

Andrea Romarheim, Sverre Lehmann, Bjørn Bjorvatn, Sahrai Saeed

{"title":"Overcoming an underdiagnosed respiratory condition: should more patients with cardiovascular complications be screened for obstructive sleep apnea?","authors":"Andrea Romarheim, Sverre Lehmann, Bjørn Bjorvatn, Sahrai Saeed","doi":"10.1080/14779072.2025.2551668","DOIUrl":"10.1080/14779072.2025.2551668","url":null,"abstract":"Introduction: Obstructive sleep apnea (OSA) - characterized by recurrent upper airway obstruction during sleep - remains underdiagnosed and undertreated. Affecting nearly one billion adults globally, OSA is especially prevalent among patients with cardiovascular comorbidities. Diagnosis may be delayed due to atypical symptoms, particularly in women, and healthcare barriers including fragmented care, limited provider training, and restricted access to specialized diagnostics. Untreated OSA contributes to an increased prevalence of resistant hypertension, recurrent arrhythmias (atrial fibrillation), stroke, and heart failure.Areas covered: This review focuses on the intricate relationship between OSA and cardiovascular health, highlighting key pathophysiological mechanisms such as intermittent hypoxia, autonomic dysregulation, and systemic inflammation that drive structural and functional cardiac impairments. Further, the review highlights the importance of improved screening tools for early detection. The special report is based on systemic search of PubMed.Expert opinion: Early screening and detection are crucial, given the strong association between untreated OSA and adverse health outcomes. Expert consensus recommends routine OSA screening in high-risk cardiovascular populations and emphasizes comprehensive early interventions; CPAP, lifestyle modification, and metabolic risk management. Integrating OSA assessment into cardiology practice and expanding advanced diagnostic tools may improve detection, reduce morbidity and mortality, and lessen the economic burden on healthcare systems.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"601-606"},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supplementation options for low serum T3 in patients with heart failure with reduced ejection fraction: could this revolutionize patient quality of life? 心力衰竭伴射血分数降低患者低血清T3的补充选择：这能彻底改变患者的生活质量吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14779072.2025.2554714

Salman Razvi

引用次数: 0

Predicting nocturnal arrhythmia episode durations to predict long-term clinical outcomes: can it be done? 预测夜间心律失常发作持续时间以预测长期临床结果：能做到吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-22 DOI: 10.1080/14779072.2025.2549431

Sobhan Salari Shahrbabaki, Anand N Ganesan

引用次数: 0

How can we reduce thrombotic and hemorrhagic events in elderly patients with atrial fibrillation? 如何减少老年房颤患者的血栓和出血事件？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1080/14779072.2025.2551682

Ilaria Maria Palumbo, Tommaso Bucci, Danilo Menichelli, Arianna Pannunzio, Emanuele Valeriani, Daniele Pastori, Pasquale Pignatelli, Gregory Y H Lip

{"title":"How can we reduce thrombotic and hemorrhagic events in elderly patients with atrial fibrillation?","authors":"Ilaria Maria Palumbo, Tommaso Bucci, Danilo Menichelli, Arianna Pannunzio, Emanuele Valeriani, Daniele Pastori, Pasquale Pignatelli, Gregory Y H Lip","doi":"10.1080/14779072.2025.2551682","DOIUrl":"10.1080/14779072.2025.2551682","url":null,"abstract":"Introduction: Life expectancy is rising globally, leading to an expected increase in age-related cardiovascular diseases. Managing cardiovascular disease in older adults is particularly challenging, as these patients often face multimorbidity, polypharmacy, and increased frailty, factors independently associated with poor prognosis and a higher risk of iatrogenic complications.Areas covered: Atrial fibrillation (AF) is the most common tachyarrhythmia worldwide, with its prevalence projected to reach 15.9 million in the U.S. by 2050 and 17.9 million in Europe by 2060, driven by the progressive aging of the population. AF patients are at high risk of thromboembolism, and oral anticoagulant (OAC) therapy remains the cornerstone of stroke prevention. However, older AF patients often have multiple comorbidities that elevate bleeding risk, making the net clinical benefit of OAC therapy uncertain.Expert opinion: This review aims to outline strategies for balancing ischemic and hemorrhagic risks in this vulnerable population, following the integrated and holistic management pathway, an evidence-based approach proven to improve outcomes in complex and frail AF patients.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"607-623"},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we improve on selecting the appropriate therapy in Brugada syndrome? 如何提高brugada综合征治疗方法的选择？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1080/14779072.2025.2549432

Paolo Compagnucci, Antonio Dello Russo, Michela Casella

引用次数: 0

Are antibiotic-eluting envelopes the solution to cardiac implantable electronic device infections? 抗生素洗脱包膜是心脏植入式电子设备感染的解决方案吗？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-09-17 DOI: 10.1080/14779072.2025.2559678

Vassil Traykov

引用次数: 0

How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease? 胆固醇外排能力如何作为动脉粥样硬化性心血管疾病的危险因素？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 DOI: 10.1080/14779072.2025.2569403

Masatsune Ogura

{"title":"How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease?","authors":"Masatsune Ogura","doi":"10.1080/14779072.2025.2569403","DOIUrl":"https://doi.org/10.1080/14779072.2025.2569403","url":null,"abstract":"Introduction: High-density lipoprotein cholesterol (HDL-C) has long been regarded as 'good cholesterol,' but clinical trials and epidemiological studies have demonstrated that simply raising HDL-C levels does not reduce cardiovascular events. Attention has therefore shifted from HDL-C quantity to HDL functionality.Areas covered: This review summarizes evidence from PubMed and Web of Science (2011-2024) on cholesterol efflux capacity (CEC), the most widely studied HDL functionality. CEC reflects the ability of HDL to remove cholesterol from macrophages, representing the first step of reverse cholesterol transport. Cohort and case-control studies consistently indicate that CEC provides incremental predictive value for atherosclerotic cardiovascular disease (ASCVD) beyond traditional lipid parameters. However, results vary across familial hypercholesterolemia cohorts, highlighting the influence of assay methods, treatment exposure, and HDL remodeling. The review also addresses lifestyle and genetic factors (e.g. alcohol consumption, ALDH2 polymorphisms), oxidative stress, and methodological challenges that complicate CEC measurement and standardization.Expert opinion: While CEC is a promising surrogate marker, it remains a phenomenon rather than a therapeutic target, and there is no conclusive evidence that increasing CEC reduces ASCVD events. Future research should focus on disease-specific molecules, such as FABP5 and ORM1, that impair HDL function. Identifying these pathways may yield novel biomarkers and therapeutic targets, offering a more precise approach to residual cardiovascular risk beyond HDL-C levels.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of functional status in patients with muscular dystrophy-associated cardiomyopathy on survival after heart transplantation. 肌萎缩相关心肌病患者的功能状态对心脏移植后生存的影响。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-10-01 Epub Date: 2025-09-14 DOI: 10.1080/14779072.2025.2559679

Sanath Patil, Nayeem Nasher, T Reese Macmillan, Daler Rahimov, Eugene Storozynsky, J Eduardo Rame, Keshava Rajagopal, John W Entwistle, Charles W Hoopes, Vakhtang Tchantchaleishvili

{"title":"Impact of functional status in patients with muscular dystrophy-associated cardiomyopathy on survival after heart transplantation.","authors":"Sanath Patil, Nayeem Nasher, T Reese Macmillan, Daler Rahimov, Eugene Storozynsky, J Eduardo Rame, Keshava Rajagopal, John W Entwistle, Charles W Hoopes, Vakhtang Tchantchaleishvili","doi":"10.1080/14779072.2025.2559679","DOIUrl":"10.1080/14779072.2025.2559679","url":null,"abstract":"Background: Heart transplant (HTx) in dystrophy patients has been shown to have a similar survival to cardiomyopathy from other causes, but postoperative rehabilitation remains an issue. This study aimed to review and analyze the reports in the literature to determine whether pre- and post-transplant functional status along with wheelchair dependence in dystrophy patients can influence post-HTx outcomes.Research design and methods: Relevant databases were queried for all case reports and case series regarding HTx in patients with dystrophy-associated cardiomyopathy published in the literature. Clinical data were extracted and tabulated. Patient survival was stratified according to preoperative and postoperative functional status, and Kaplan-Meier survival analysis was performed.Results: We identified 22 studies yielding 36 patients with muscular dystrophy who underwent HTx. At baseline, there were three patients who were wheelchair dependent, and 22 patients had a diminished functional status preoperatively. Overall survival did not differ significantly between patients with normal baseline functional status and those with diminished functional status, either before or after transplantation.Conclusions: Although no significant survival difference was found, diminished functional status, both pre- and post-transplant, appear to be associated with worse survival, highlighting its importance in transplant decision-making.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"625-633"},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0